Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01161654 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions
A NA study of Migraine, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01161654: Completed NA study of Migraine, sponsored by Roxane Laboratories.
NCT01161654 is a NA study of Migraine that has completed, run by Roxane Laboratories. The registered enrollment target is 33 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01161654, a NA study of Migraine, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was to prove the bioequivalence of Naratriptan Hydrochloride Tablet under fed conditions.
Conditions Studied
Interventions
- DRUG naratriptan hydrochoride
Study Locations (1)
Washington
- Charles River Northwest Kinetics - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-09 |
| Phase | NA |
What the finished NCT01161654 record still lists
NCT01161654 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which naratriptan hydrochoride is the first listed.
NCT01161654 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT01161654 about?
NCT01161654 is a clinical study titled "Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions". The objective of this study was to prove the bioequivalence of Naratriptan Hydrochloride Tablet under fed conditions.
What is the current status of trial NCT01161654?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2007-08. Estimated completion is 2007-09.
What conditions does trial NCT01161654 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT01161654?
The interventions under investigation include: naratriptan hydrochoride (DRUG).
Who is sponsoring clinical trial NCT01161654?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01161654 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01161654's enrollment target sits among peer trials
33 90th of 102 higher than 13 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Cocoa Extract for Migraine Trial
RECRUITING · NA
-
Migraine in Adolescents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia